We are live on ! Find out more
TLOG

TetraLogic Pharmaceuticals
TLOG

Delisted

TLOG was delisted on the 3rd of November, 2016.

19 hedge funds and large institutions have $205K invested in TetraLogic Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.86% less ownership

Funds ownership: 3.54% → 2.68% (-0.86%)

24% less funds holding

Funds holding: 25 → 19 (-6)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

84% less capital inflows, than outflows

Capital inflows: $7.31K | Capital outflows: $46.8K

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
19
Holders Change
-6
Holders Change %
-24%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

TLOG Hedge Fund Activity: Q2 2016 in Review

19 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in TetraLogic Pharmaceuticals (TLOG) for Q2 2016, worth a combined $205K — up 34% from $153K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TLOG and 1 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 2 added.

The largest buyer was Vanguard Group, adding an estimated $7.22K. The largest seller was Lazard Asset Management, exiting entirely with an estimated $13K sold.

  • 19 institutional investors held TetraLogic Pharmaceuticals (TLOG) as of Q2 2016, down from 25 in Q1 2016.
  • Funds reported $205K of TetraLogic Pharmaceuticals stock for Q2 2016, up 34% quarter-over-quarter.
  • 1 fund opened new TetraLogic Pharmaceuticals positions in Q2 2016 and 7 closed out, a net change of -6 holders.
  • The largest TetraLogic Pharmaceuticals buyer in Q2 2016 was Vanguard Group, an estimated $7.22K added.
  • The largest TetraLogic Pharmaceuticals seller in Q2 2016 was Lazard Asset Management, an estimated $13K sold.

Based on aggregated 13F filings for Q2 2016.